Evox Therapeutics was established in 2016 to advance leading edge science from Oxford University and the Karolinska Institute. We work to develop innovative exosome therapeutics for diseases with significant unmet medical need.
Backed by leading venture capital groups and leveraging a comprehensive dominant intellectual property portfolio Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of rare and severe diseases with limited treatment options for patients and their families.
We have already recruited exceptional people working in multidisciplinary teams, sharing our mission to transform how we treat rare diseases. Why not join our team and make your contribution to our journey ahead.